---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-047759"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:40:04.123391+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apellis prices $350M public offering of common stock and pre-funded warrants

## Summary
- Offering of 3,174,603 shares at $63.00/share and pre-funded warrants for 2,380,956 shares at $62.9999/warrant.
- Total gross proceeds ~$350M; net proceeds ~$333M (or ~$383M if underwriters' option exercised).
- Underwriters granted 30-day option to purchase up to 833,333 additional shares.
- Expected closing February 27, 2023; net proceeds to fund operations into Q1 2025.
- J.P. Morgan, Goldman Sachs, and Evercore acting as joint book-running managers.

## SEC filing metadata
- accession: 0001193125-23-047759
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523047759/0001193125-23-047759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523047759/d454389d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-047759
- JSON: https://secwatch.observer/filing/0001193125-23-047759.json
- Plain text: https://secwatch.observer/filing/0001193125-23-047759.txt

## Key facts
- Material Agreements
  Apellis Pharmaceuticals, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. valued at approximately $333.0 million (effective 2023-02-22).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C.
  - Value: approximately $333.0 million
  - Effective: 2023-02-22
  source text: On February 22, 2023, Apellis Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 3,174,603 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and, in lieu of Common Stock to investors who so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,380,956 shares of Common Stock (the “Warrant Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523047759/0001193125-23-047759-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.